NAMs Gain Traction in Preclinical Drug Development, Driven by Regulatory Shifts and Data

The past year has marked a significant turning point for New Approach Methodologies (NAMs) in preclinical drug development. These human-relevant approaches are no longer experimental curiosities; they have rapidly gained traction, driven by a growing evidence pool and major regulatory reforms. Regulators are under increasing pressure to support drug developers in moving beyond in vivo animal testing, recognizing that NAMs can bring new treatment options to patients faster and with greater predictive accuracy.

The Status Quo of Drug Discovery and Development

Animal research has historically been central to drug discovery, allowing researchers to evaluate how drugs behave in a whole living system before human trials. However, the disconnect between preclinical labs and clinical outcomes is stark: only one in ten drugs entering phase I trials goes on to receive regulatory approval. These failures are not only costly but also result in unnecessary animal use, driven by inter-species differences that limit the predictive value of animal models.

Regulatory Shifts Accelerate NAM Adoption

2025 saw unprecedented regulatory shifts that have brought NAMs into the spotlight. The US FDA announced plans to phase out animal testing requirements for monoclonal antibodies and other drugs, while the UK Government unveiled a roadmap to phase out animal testing faster in favor of alternative methods. These moves have led to a clear acceleration in the market, similar to the early days of organ-on-a-chip (OOC) technology, which saw growth rates of up to 40%.

These regulatory changes have prompted a sharp uptick in interest from scientists across academia and industry. Researchers who previously overlooked NAMs are now exploring their potential, and those already considering them have made the leap to purchase and gather data. This increased confidence is driving deeper investment in these technologies.

Key Takeaways

• Regulatory Support: Major regulatory bodies like the US FDA and UK Government are pushing for a reduction in animal testing, accelerating NAM adoption.
• Predictive Accuracy: NAMs offer greater predictive accuracy compared to traditional animal models, reducing drug failure rates and unnecessary animal use.
• Market Growth: The market is seeing significant growth, with technologies like organ-on-a-chip showing up to 40% growth rates.
• Research Interest: Scientists are increasingly interested in NAMs, leading to more data and deeper investment.

The shift towards NAMs represents a paradigm change in drug development. As regulatory support grows and more data becomes available, these methodologies will likely become a core aspect of modern drug discovery, ensuring that the next generation of therapies is both effective and humane.